airway obstruction and not against its causes will not be beneficial.

1 AMIRAY Paediatric Department, Rebecca Siff Government Hospital, 13100 Salé, Tmar

Dr Skoner and Fireman comment:
In response to Dr Amiray: (1) Persistence of post treatment rises of the measured prostaglandin F₂α metabolite were not unexpected, as this metabolite is stable in plasma and may be detectable for hours after the release of prostaglandin F₂α, which has a relatively short half life. (2) All of the infants in group II (infants after treatment) had residual signs of airway obstruction. (3) Pulmonary function testing would certainly be superior to measuring parameters in assessing the degree of airway obstruction, but this methodology was unavailable and may be unreliable in infants. (4) Inflammatory mediators are released either as a primary event causative of a disease process or as a secondary event, which may not be related to pathophysiology. In either case, the relationship of the mediator to the pathophysiological process is very complex, as inflammation is likely an orchestrated response, with release of multiple mediators simultaneously and synergism or antagonism between various mediators in provoking pathophysiologies. Additionally, the desired human pathophysiological response may be inaccessible to direct measurement. As such, absolute proof of a causal relationship between a mediator and a pathophysiological process is frequently lacking and rests on a body of indirect rather than direct evidence.

Three criteria for implicating a mediator in disease pathophysiology are generally accepted: (1) recovery at or near the site of active disease; (2) reproduction by exposure to the mediator; and (3) attenuation or prevention by pretreatment with a mediator antago- nist. The results of our study indicate that a metabolite of prostaglandin F₂α was detectable in plasma during acute airway obstruction and satisfy criteria (1). Other investigators have documented that inhaled prostaglandin F₂α can cause bronchoconstriction (criteria 2). This evidence, although suggestive, is insufficient to prove a causal relationship. In situations such as this, clinical trials with specific antagonists (criteria 3) can provide confirmation that a given mediator participates in a pathophysiological process. For this reason, we believe that therapeutic trials using specific anti-inflammatory agents for the treat- ment of airway obstruction are warranted.


Diagnostic accuracy of pH monitoring in gastro-oesophageal reflux

Str.—Da Dalt and colleagues believe their data show that a pH study has 100% sensiti- vity and 94% specificity for the diagnosis of gastro-oesophageal reflux. In particular, in their discussion they make comment of the fact that they did not find any false negatives and conclude that a negative result must be thought of as being sufficient to rule out gastro-oesophageal reflux.

In order to comment about the sensitivity or specificity, a comparison must be made with a gold standard. As a gold standard, the authors have chosen 24 hour pH monitoring, with reflux being classified as present if at least two episodes of spontaneous reflux were present in five minutes (according to Meyers et al' ). A biopsy was performed in all our patients, and the signs of oesophagitis were always present.

Finally we agree with Dr Henry that not all children who vomit need a pH study or other examinations, but think that when a major clinical problem is present an important gastro-oesophageal reflux is suspected, admis- sion is to be considered. An alternative could be to perform an ambulatory 24 hour pH study; this has recently been attempted even in children.


A catabolic state in dexethasone treatment of bronchopulmonary dysplasia

Str.—Dexethasone treatment is being increasingly used in babies with broncho- pulmonary dysplasia because of its benefit. We have reviewed the effect of treatment in the first nine infants we have treated. All were infants with bronchopul- monary dysplasia who had been ventilated from birth for respiratory distress syndrome. Gestation ranged from 25 to 30 weeks (mean 27+5) and birth weight ranged from 740 to 1510 g (mean 1050). Four babies had required surgical ligation of a patent ductus arteriosus. Dexethasone was commenced between days 32 and 67, and the dosage varied between 0.46 and 2.13 mg/kg/ day (mean 1.07). The infants' ventilatory requirement had been either static or deteriorating over the week before treatment. We found the treatment effective in the short term managing successfully to extubate all the infants within a week and seven of nine by the third day of treatment.

There has been concern over the incidence of side effects including hypertension, septi- caemia, necrotising enterocolitis, hyper- glycaemia, and the possibility of longer term adrenal suppression. In our patients infection, hyperthermia, and hyperglycaemia did not cause any real problem. Three of our nine patients, however, required prolonged courses in excess of five weeks to maintain the effect and appeared to exchange dexethasone for ventilator dependency; this is of particular concern with regard to possible adrenal sup- pression.

We would highlight the fact that a pronounced catabolic state as documented on commencing treatment, to our knowledge this has not been commented on in previous reports. Mean weight gain fell to ~57 g/week from ~350 g/week before treatment. For any weight in the first week of treatment and all had previously been gaining weight. Blood urea concentrations averaged over the first week on treatment were 5.4±3 times those of patients with an abnormal pH study we performed a barium swallow and/or oesophago- scopy especially in order to rule out structural anomalies; however a radiological gastro-oesophageal reflux was diagnosed in at least two episodes of spontaneous reflux were present in five minutes (according to Meyers et al'). A biopsy was performed in all our patients, and the signs of oesophagitis were always present.

R L HENRY The University of Newcastle, Rankin Drive, Newcastle, NSW 2308, Australia
